🟡 Medium ImpactPharma
Lupin gets FDA nod for famotidine injection.
Lupin gets FDA nod for famotidine injection. The company received U.S. FDA approval for its generic famotidine injection, USP, strengthening its hospital products portfolio. This approval allows Lupin to launch the injectable anti-ulcer drug in the U.S. market. The product had $120 million in annual sales in the U.S. over the past 12 months.
📊 STOCKS: LUPIN | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #FDAApproval
#FDAApproval#Lupin#GenericDrug
Stocks mentioned
⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.
Trade smarter on NSE
Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.
Start for ₹1 →